PMID- 21658434
OWN - NLM
STAT- MEDLINE
DCOM- 20130404
LR  - 20220310
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1816
IP  - 2
DP  - 2011 Dec
TI  - The multiple roles of amphiregulin in human cancer.
PG  - 119-31
LID - 10.1016/j.bbcan.2011.05.003 [doi]
AB  - Amphiregulin (AREG) is one of the ligands of the epidermal growth factor receptor 
      (EGFR). AREG plays a central role in mammary gland development and branching 
      morphogenesis in organs and is expressed both in physiological and in cancerous 
      tissues. Various studies have highlighted the functional role of AREG in several 
      aspects of tumorigenesis, including self-sufficiency in generating growth 
      signals, limitless replicative potential, tissue invasion and metastasis, 
      angiogenesis, and resistance to apoptosis. The oncogenic activity of AREG has 
      already been described in the most common human epithelial malignancies, such as 
      lung, breast, colorectal, ovary and prostate carcinomas, as well as in some 
      hematological and mesenchymal cancers. Furthermore, AREG is also involved in 
      resistance to several cancer treatments. In this review, we describe the various 
      roles of AREG in oncogenesis and discuss its translational potential, such as the 
      development of anti-AREG treatments, based on AREG activity. In the last decade, 
      independent groups have reported successful but sometimes contradictory results 
      in relation to the potential of AREG to serve as a prognostic and/or predictive 
      marker for oncology, especially with regard to anti-EGFR therapies. Thus, we also 
      discuss the potential usefulness of using AREG as a therapeutic target and 
      validated biomarker for predicting cancer outcomes or treatment efficacy.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Busser, Benoit
AU  - Busser B
AD  - INSERM, U823, Institut Albert Bonniot, Grenoble, France, Universite Joseph 
      Fourier, Grenoble, France. bbusser@chu-grenoble.fr
FAU - Sancey, Lucie
AU  - Sancey L
FAU - Brambilla, Elisabeth
AU  - Brambilla E
FAU - Coll, Jean-Luc
AU  - Coll JL
FAU - Hurbin, Amandine
AU  - Hurbin A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110530
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (EGF Family of Proteins)
RN  - 0 (Glycoproteins)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Amphiregulin
MH  - Animals
MH  - Drug Resistance, Neoplasm
MH  - EGF Family of Proteins
MH  - ErbB Receptors/physiology
MH  - Glycoproteins/antagonists & inhibitors/chemistry/*physiology
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/chemistry/*physiology
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neoplasms/*etiology
MH  - Prognosis
EDAT- 2011/06/11 06:00
MHDA- 2013/04/05 06:00
CRDT- 2011/06/11 06:00
PHST- 2011/04/04 00:00 [received]
PHST- 2011/05/20 00:00 [revised]
PHST- 2011/05/21 00:00 [accepted]
PHST- 2011/06/11 06:00 [entrez]
PHST- 2011/06/11 06:00 [pubmed]
PHST- 2013/04/05 06:00 [medline]
AID - S0304-419X(11)00024-2 [pii]
AID - 10.1016/j.bbcan.2011.05.003 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2011 Dec;1816(2):119-31. doi: 10.1016/j.bbcan.2011.05.003. 
      Epub 2011 May 30.